




MEMBERSHIP PROSPECTUS

The Personalized Medicine Coalition, representing innovators, scientists, patients, providers, and payers, promotes the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.

 www.personalizedmedicineconference.org
 www.personalizedmedicinecoalition.org




PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE AND NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on this assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics. Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual's medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.






PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers, and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers and patients about how the field can make health systems more effective and efficient by targeting better treatments to only those who will benefit.
- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage, and payment policies that support access to personalized medicine.
- **Evidence Development:** To encourage the swifter adoption of personalized medicine by payers and health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.





PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- **Public Policy Committee**

- Patient Advocacy Organization Working Group
- Pharmaceutical and Diagnostics Working Group

- **Science Policy Committee**

- Health Care Working Group
- Value Assessment Working Group

- **Additional Working Groups**

- Health Data Working Group
- Pharmacogenomics Working Group

MEMBER BENEFITS

- **Contact 2,000+ leaders in personalized medicine via PMC's member database**
- **Interact with 200+ thought leaders from Congress, FDA, CMS and the private sector at member meetings and events**
- **Save 40% on registration for the Annual Personalized Medicine Conference**
- **Attend Member Meetings and Events at no charge**
- **Receive Copies of PMC publications and reports**



2027 MEMBERSHIP

Join the Personalized Medicine Coalition

PMC membership gives your organization a voice in the conversations shaping personalized medicine and a place at the table with the leaders working to advance it.

Membership Category

2027 Annual Dues

Large Public Corporation	\$42,000
Small Public Corporation	\$21,000
Trade Association	Based on revenues
Private Corporation, >15 FTEs	\$7,800
Private Corporation, <15 FTEs	\$3,850
Professional Society	Based on revenues
Strategic Partner, >5 FTEs	\$4,100
Strategic Partner, <5 FTEs	\$1,880
Research, Education & Clinical Care Institution	\$3,850
Patient Advocacy Group	\$500

To see a list of current members, please visit our website at <https://www.personalizedmedicinecoalition.org/membership/>

For more information on membership opportunities, contact Ancilla Brady, Director of Membership and Business Development, at abrady@personalizedmedicinecoalition.org.

STAFF

Gina Ross Murdoch, MBA - President and CEO
Cynthia A. Bens - Senior Vice President, Public Policy
Ancilla Brady - Director of Membership and Business Development
Christopher Brownlowe - Director of Operations
Eric Mahoney - Associate Vice President, Science & Research
Darion Banister - Director of Research Strategy and Partnerships



PMC BOARD OF DIRECTORS

Lauren Silvis, J.D.

Board Chair

Senior Vice President of External Affairs, Tempus

Sarah Hersey, M.S., M.B.A., R.A.C.

Board Vice Chair

Vice President, Precision Medicine, Bristol Myers Squibb

Richard Knight, MBA

Board Treasurer

Past President, American Association of Kidney Patients

Brian Caveney, M.D.

Board Secretary

Chief Medical & Scientific Officer, Labcorp

Lincoln D. Nadauld, M.D., Ph.D.

Past Board Chair

Chief Medical Officer, Valinor

Okan Ekinci, MD, MBA

Global Head of Digital Technology and Chief Medical Information Officer, Roche Information Solutions

Helmy Eltoukhy, Ph.D.

Chairman, Co-CEO, Co-Founder, Guardant Health

Andrea Ferris, MBA

President & CEO, LUNGEvity Foundation

Megan P. Hall, PhD

Vice President of Medical & Corporate Affairs and Distinguished Scientist, GRAIL, Inc.

Ryan Hutto, M.A.

Head of Commercial Diagnostics, Pfizer

James W. Lillard, Ph.D.

Senior Associate Dean, Morehouse School of Medicine

Howard McLeod, Pharm.D.

Managing Director, Clarified Precision Medicine

Sharon Moulis, Ph.D.

Independent

Elizabeth O'Day, Ph.D.

CEO, Olaris

Omar Perez, Ph.D.

Independent

Kristin Ciriello Pothier

Principal, US and Americas Region Life Sciences Sector Leader and Global Deal Advisory and Strategy Leader, Healthcare and Life Sciences, KPMG

Prasanth Reddy, M.D.

Chief Medical Officer, Mercy BioAnalytics, Inc.

Anthony Sireci, MD, MSc

Senior Vice President of Clinical Biomarkers, Laboratories and Diagnostics, Eli Lilly and Company

Andrea Stevens, Ph.D.

Interim Head, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Apostolia M. Tsimberidou, M.D., Ph.D.

Professor, Department of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center

Cecilia Schott, Pharm.D.

Vice President, Head of Precision Medicine Portfolio Planning, GlaxoSmithKline

Michael Ybarra, M.D.

Senior Vice President and Chief Medical Officer, PhRMA